Cherifi François, Lefevre Arbogast Sophie, Font Jonaz, Abdeddaim Cyril, Becourt Stephanie, Penel Nicolas, Coquan Elodie, Lequesne Justine, Gidron Yori, Joly Florence
Department of Medical Oncology, Centre François Baclesse, Caen, France.
Department of Clinical Research, Centre Francois Baclesse, Caen, France.
Front Oncol. 2022 Nov 29;12:1049970. doi: 10.3389/fonc.2022.1049970. eCollection 2022.
Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate variability (HRV), may predict poor cancer prognosis. We aimed to examine the prognostic value of HRV in OC.
This bicentric retrospective study included patients diagnosed with serous OC FIGO stage ≥IIB, between January 2015 and August 2019, with electrocardiograms (ECG) available around diagnosis. HRV was measured from ECG using the time domain parameter of standard deviation of all normal-to-normal heartbeat intervals (SDNN). Optimal SDNN cut-off was determined using the Youden index criteria of time-dependent ROC curves. We used multivariate cox proportional hazard models to investigate the association between HRV and overall survival (OS), while adjusting for well-known OC prognostic factors.
The 202 patients included were 65.7 years-old on average, 93% had stage FIGO IIIC/IV, 56% had complete surgical resection. Median OS was 38.6 months [95%CI:34.4-47.4]. The median SDNN was 11.1ms, with an optimal cut-off of 10ms to predict OS. OS was shorter for patients with low HRV compared to high HRV (26.4 vs 45.1 months; p<0.001). In multivariate analysis, HRV remained an independent prognostic factor with a two-fold higher risk of death among patients with low SDNN compared to those with high SDNN (HR=2.03, 95%CI=1.35-3.06, p<0.001).
Low HRV, was associated with worse OS in OC patients, supporting previous studies on the prognostic role of HRV in cancer. If replicated in prospective studies, vagal nerve activity may be a new therapeutic target in OC.
识别新的可改变的预后标志物对卵巢癌(OC)至关重要。副交感神经活动降低与炎症、氧化应激和交感神经系统激活有关。先前的研究报道,通过低心率变异性(HRV)测量的迷走神经活动降低可能预示癌症预后不良。我们旨在研究HRV在OC中的预后价值。
这项双中心回顾性研究纳入了2015年1月至2019年8月期间诊断为浆液性OC且国际妇产科联盟(FIGO)分期≥IIB期、诊断时可获得心电图(ECG)的患者。使用所有正常心跳间期标准差(SDNN)的时域参数从ECG中测量HRV。使用时间依赖性ROC曲线的约登指数标准确定最佳SDNN临界值。我们使用多变量考克斯比例风险模型来研究HRV与总生存期(OS)之间的关联,同时对已知的OC预后因素进行校正。
纳入的202例患者平均年龄为65.7岁,93%为FIGO IIIC/IV期,56%接受了完整的手术切除。中位OS为38.6个月[95%置信区间:34.4 - 47.4]。中位SDNN为11.1ms,预测OS的最佳临界值为10ms。与高HRV患者相比,低HRV患者的OS更短(26.4个月对45.1个月;p<0.001)。在多变量分析中,HRV仍然是一个独立的预后因素,与高SDNN患者相比,低SDNN患者的死亡风险高出两倍(HR = 2.03,95%置信区间 = 1.35 - 3.06,p<0.001)。
低HRV与OC患者较差的OS相关,支持先前关于HRV在癌症中预后作用的研究。如果在前瞻性研究中得到验证,迷走神经活动可能成为OC的一个新的治疗靶点。